IceCure Medical (NASDAQ:ICCM) Announces Earnings Results

IceCure Medical (NASDAQ:ICCM) announced its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), Zacks reports. The company had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%.

IceCure Medical Stock Performance

Shares of ICCM stock traded down $0.02 on Friday, reaching $1.08. The stock had a trading volume of 51,492 shares, compared to its average volume of 519,416. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $60.16 million, a price-to-earnings ratio of -3.72 and a beta of 0.37. The firm’s 50-day moving average is $1.32 and its two-hundred day moving average is $0.98.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $2.50 target price on shares of IceCure Medical in a report on Friday.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.